Media stories about BioSpecifics Technologies Corp (NASDAQ:BSTC) have trended somewhat positive this week, Accern reports. Accern ranks the sentiment of media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. BioSpecifics Technologies Corp earned a coverage optimism score of 0.24 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 85 out of 100, meaning that recent media coverage is very likely to have an impact on the company’s share price in the near future.
Shares of BioSpecifics Technologies Corp (NASDAQ:BSTC) traded down 1.50% during trading on Friday, hitting $45.21. The company had a trading volume of 33,562 shares. BioSpecifics Technologies Corp has a 1-year low of $35.79 and a 1-year high of $58.79. The company’s 50 day moving average is $49.71 and its 200 day moving average is $51.93. The firm has a market capitalization of $323.97 million, a P/E ratio of 27.74 and a beta of 1.76.
BSTC has been the topic of a number of recent research reports. HC Wainwright set a $72.00 target price on BioSpecifics Technologies Corp and gave the stock a “buy” rating in a report on Thursday. BidaskClub cut BioSpecifics Technologies Corp from a “hold” rating to a “sell” rating in a report on Wednesday, August 2nd. Finally, Zacks Investment Research upgraded BioSpecifics Technologies Corp from a “sell” rating to a “hold” rating in a report on Tuesday, July 11th.
COPYRIGHT VIOLATION NOTICE: This piece was originally reported by Community Financial News and is the property of of Community Financial News. If you are reading this piece on another site, it was stolen and republished in violation of U.S. and international copyright & trademark laws. The original version of this piece can be read at https://www.com-unik.info/2017/08/11/biospecifics-technologies-corp-nasdaqbstc-earns-media-impact-score-of-0-24-updated-updated-updated.html.
About BioSpecifics Technologies Corp
BioSpecifics Technologies Corp. is a biopharmaceutical company involved in the development of an injectable collagenase clostridium histolyticum for multiple indications. The Company has a development and license agreement with Endo Global Ventures, a Bermuda unlimited liability company (Endo Global Ventures), an affiliate of Endo International plc (Endo), for injectable collagenase for marketed indications and indications in development.
What are top analysts saying about BioSpecifics Technologies Corp? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for BioSpecifics Technologies Corp and related companies.